Summary
Global Markets Direct’s, ‘Lyme Disease - Pipeline Review, H2 2016’, provides an overview of the Lyme Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Lyme Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Lyme Disease
- The report reviews pipeline therapeutics for Lyme Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lyme Disease therapeutics and enlists all their major and minor projects
- The report assesses Lyme Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lyme Disease
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lyme Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lyme Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
LondonPharma Ltd
NovoBiotic Pharmaceuticals, LLC
Valneva SE
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lyme Disease Overview 6
Therapeutics Development 7
Pipeline Products for Lyme Disease - Overview 7
Lyme Disease - Therapeutics under Development by Companies 8
Lyme Disease - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Lyme Disease - Products under Development by Companies 12
Lyme Disease - Companies Involved in Therapeutics Development 13
LondonPharma Ltd 13
NovoBiotic Pharmaceuticals, LLC 14
Valneva SE 15
Lyme Disease - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
azithromycin - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
lyme disease vaccine 2 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Nu-3 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecule for Lyme Disease - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules for Lyme Disease - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
VLA-15 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Lyme Disease - Dormant Projects 32
Lyme Disease - Product Development Milestones 33
Featured News & Press Releases 33
Mar 24, 2016: VALNEVA to present at the 16th World Vaccine Congress in Washington D.C. 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35
List of Tables
Number of Products under Development for Lyme Disease, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Lyme Disease - Pipeline by LondonPharma Ltd, H2 2016 13
Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016 14
Lyme Disease - Pipeline by Valneva SE, H2 2016 15
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Lyme Disease - Dormant Projects, H2 2016 32
List of Figures
Number of Products under Development for Lyme Disease, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Targets, H2 2016 17
Number of Products by Stage and Targets, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 19
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Routes of Administration, H2 2016 21
Number of Products by Stage and Routes of Administration, H2 2016 21
Number of Products by Molecule Types, H2 2016 23
Number of Products by Stage and Molecule Types, H2 2016 23
